Understanding how BARD1 helps repair DNA and regulate gene expression
Defining the role of BARD1 in nucleosomal ubiquitylation
This study is looking at how a protein called BARD1, which is linked to breast and ovarian cancer, helps fix DNA and control genes, to better understand how changes in this protein might lead to cancer, which could help doctors predict the impact of certain mutations in patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-11063213 on NIH RePORTER |
What this research studies
This research investigates the role of BARD1, a protein associated with breast and ovarian cancer, in the processes of DNA damage repair and gene regulation. By examining how BARD1 interacts with other proteins and its function as an E3 ubiquitin ligase, the study aims to uncover the molecular mechanisms that may lead to cancer when BARD1 is mutated. The research employs advanced biophysical techniques to analyze these interactions and their implications for hereditary cancer predisposition. Ultimately, the findings could help predict the effects of specific mutations in patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with a family history of breast or ovarian cancer, particularly those with mutations in the BRCA1 or BARD1 genes.
Not a fit: Patients without a hereditary predisposition to breast or ovarian cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to better understanding and management of hereditary breast and ovarian cancers.
How similar studies have performed: Previous research has shown promising results in understanding the roles of similar proteins in cancer biology, indicating that this approach has the potential for significant insights.
Where this research is happening
Seattle, United States
- University of Washington — Seattle, United States (Active)
Researchers
- Principal investigator: Klevit, Rachel E — University of Washington
- Study coordinator: Klevit, Rachel E
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.